What to Know About Each FDA-Approved Agent for Spinal Muscular Atrophy
  • CME
  • CE

With 3 FDA-approved agents now available for SMA, here’s my summary of the most clinically important information to help you educate families and assist them in making decisions about treatment.
Nancy L. Kuntz, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Nurse Practitioners: 0.25 NAPNAP CE contact hours
Released: October 23, 2020 Expiration: October 22, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the safety and efficacy profiles of currently available and emerging agents for the management of SMA

Acknowledgements

Provided by Clinical Care Options, in collaboration with the National Association of Pediatric Nurse Practitioners

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

 

5 Hanover Square, Suite 1401
New York, NY 10004
Phone: 877-662-7627
Email: info@napnap.org

Supported by educational grants from
Biogen
Genentech, a member of the Roche Group

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Nancy L. Kuntz, MD

Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Medical Director
Mazza Foundation Neuromuscular Disorders Program
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois

Nancy L. Kuntz, MD, has disclosed that she has received consulting fees from AveXis, Biogen, Cytokinetics, and Genentech.

Staff

Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for neurologists, pediatricians, hospitalists, primary care physicians, nurse practitioners, physician assistants, and other healthcare professionals who care for patients with SMA.

Goal

The goal of this activity is to increase the knowledge and competence of clinicians and healthcare providers in the recognition, assessment, diagnosis, and management of patients with SMA to improve patient outcomes.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the National Association of Pediatric Nurse Practitioners . Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

Accreditation Statement

This program is accredited for 0.25 NAPNAP CE contact hours of which 0.25 contain pharmacology content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 23, 2020, through October 22, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on how to support, counsel, and educate families with a new diagnosis of spinal muscular atrophy (SMA), from Clinical Care Options (CCO)

Vanessa Battista, MS, RN, CPNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 5, 2020 Expired: October 4, 2021

Expert slides from Clinical Care Options on screening, diagnosis, treatment, and interdisciplinary care for spinal muscular atrophy (SMA)

Samiah Al-Zaidy, MD Vanessa Battista, MS, RN, CPNP Nancy L. Kuntz, MD Released: September 3, 2020

Expert video from Clinical Care Options (CCO) on screening, diagnosis, and interdisciplinary management of spinal muscular atrophy (SMA)

Samiah Al-Zaidy, MD Vanessa Battista, MS, RN, CPNP Nancy L. Kuntz, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Nurse Practitioners: 1.25 NAPNAP CE contact hours Released: September 3, 2020 Expired: September 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue